Novel genistein derivatives induce cell death and cell cycle arrest through different mechanisms

Nutrition and Cancer

Volumn 65, Issue 6, 2013, Pages 874-884

  Switalska, Marta ^a   Grynkiewicz, Grzegorz ^a   Strzadala, Leon ^a   Wietrzyk, Joanna ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CMG G; GENISTEIN; GENISTEIN DERIVATIVE; IFG 001; IFG 018; IFG 027; IFG 032; IFG 034; IFG 036; IFG 037; IFG 038; IFG 042; IFG 043; IFG 046; IFG 048; IFG 051; IFG 052; IFG 053; IFG 054; IFG 057; SPG G; UNCLASSIFIED DRUG; VALINOMYCIN; XG G;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL STRAIN HL 60; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 84882446175     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.804938     Document Type: Article

References (60)

1. Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, et al.: Soybean phytoestrogen intake and cancer risk. J Nutr 125, 757-770, 1995.
2. Knight DC and Eden JA: A review of the clinical effect of phytoestrogens. Obstet Gynecol 87, 897-904, 1994.
3. Lampe JW, Nishino Y, Ray RM,Wu C, LiW, et al.: Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 16, 2579-2586, 2007.
4. Adlercreutz H, Markkanen H, and Watanabe S: Plasma concentration of phyto-oestrogens in Japanese men. Lancet 342, 1209-1210, 1993.
5. Mills PK, Beeson WL, Phillips RL, and Fraser GE: Cohort study of diet lifestyle and prostate cancer in Adventist men. Cancer 64, 598-604, 1989.
6. Nagata C, Takatsuka N, Kawakami N, and Shimizu H: A prospective cohort study of soy produkt intake and stomach cancer death. Br J Cancer 87, 31-36, 2002.
7. Messina MJ, Persky V, Setchell KD, and Barnes S: Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 21, 113-131, 1994.
8. Shimazu T, Inoue M, Sasazuki S, Iwasaki M, Sawada N, et al.: Isoflavone intake and risk of lung cancer: A prospective cohort study in Japan. Am J Clin Nutr 91, 722-728, 2010.
9. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR, et al.: Dietary phytoestrogens and lung cancer risk. JAMA 294, 1493-1504, 2005.
10. Horn-Ross PJ, Hoggat KJ, and Lee MM: Phytoestrogens and thyroid cancer risk. Cancer Epidemiol. Biomarkers Prev 11, 43-49, 2002.
11. Alhasan SA, Aranha O, and Sarkar FH: Genistein elicits pleiotropic molecular effects on head and neck cancer cell. Clin Cancer Res 7, 4174-4181, 2001.
12. Severson RK, Nomura AM, Grove JS, and Stemmermann GN: A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 49, 1857-1860, 1989.
13. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe SI, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262, 5592-5595, 1987.
14. Bandele OJ and Osheroff N: Bioflavonoids as poisons of human topoisomerase IIα and IIα. Biochemistry 46, 6097-6108, 2007.
15. Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, et al.: The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochemical Pharmacology 69, 307-318, 2005.
16. Banerjee S, Li Y,Wang Z, and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Letters 269, 226-242, 2008.
17. Li Y, Upadhyay S, Bhuiyan M, and Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18, 3166-3172, 1999.
18. Li Y, Achmed F, Ali S, Philip PA, Kucuk O, et al.: Inactivation of Nuclear Factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65, 6934-6942, 2005.
19. Alhasan SA, Ensley JF, and Sarkar FH: Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int J Oncol 16, 333-338, 2000.
20. Natarajan K, Manna SK, Chaturvedi MM, and Aggarwal BB: Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65 and subsequent gene expression. Arch Biochem Biophys 352, 59-70, 1998.
21. Casagrande F and Karbon JM: P21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp Cell Res 258, 101-108, 2000.
22. Davis JN, Singh B, Bhuiyan M, and Sarkar FH: Genistein induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32, 123-131, 1998.
23. Lian F, BhuiyanM, Li YW,Wall N, KrautM, et al.: Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31, 184-191, 1998.
24. Luo H, Jiang BH, King SM, and Chen YC: Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer 60, 800-809, 2008.
25. Farina HG, Pomiéc M, Alonso DF, and Gomez DE: Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse model of melanoma and breast cancer. Oncology Reports 16, 885-891, 2006.
26. Constantinou A and Huberman E: Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc Soc Exp Biol Med 208, 109-115, 1995.
27. Sanchez Y, Amran D, de Blas E, and Aller P: Regulation of genisteininduced differentiation in human acute myeloid leukemia cells (HL60, NB4) Protein kinase modulation and reactive oxygen species generation. Biochem Pharmacol 77, 384-396, 2009.
28. Gossner G, Choi M, Tan L, Fogoros S, and Griffith KA: Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecologic Oncology, 23-30, 2007.
29. Zava DT and Duwe G: Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 27, 31-40, 1997.
30. Ogawara H, Akiyama T, Watanabe S, Ito N, Kobori M, et al.: Inhibiton of tyrosine protein kinase activity by synthetic isoflavones and flavones. J Antibiot 42, 340-343, 1989.
31. Peterson G: Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 125(Suppl), 784-789, 1995.
32. Zhang T, Wang F, Xu HX, Yi L, Qin Y, et al.: Activation of nuclear factor erythroid 2-related factor 2 and PPARγ plays a role in the genisteinmediated attenuation of oxidative stress-induced endothelial cell injury. Br J Nutr 109, 223-235, 2013.
33. Popiołkiewicz J, Polkowski K, Skierski JS, and Mazurek AP: In vitro toxicity evaluation in the development of new anticancer drugs: Genistein glycosides. Cancer Lett 229, 67-75, 2005.
34. Rusin A., Gogler A., Głowala-Kosínska M., Bochenek D., Gruca A., et al. Unsaturated genistein disaccharide glycoside as a novel agent affecting microtubules. Bioorganic & Medical Chemistry Letters 19, 4939-4943, 2009.
35. Tchize Ndejouong BLS, Sattler I, Dahse HM, Kothe E, and Hertweck C: Isoflavoneswith unusually modified B-rings and their evaluation as antiproliferative agents. Bioorganic & Medical Chemistry Letters 19, 6473-6476, 2009.
36. Choi JN, Kim D, Choi HK, Yoo KM, Kim J, et al.: 2'-hydroxylation of genistein enhanced antioxidant and antiproliferative activities in MCF-7 human breast cancer cells. J Microbiol Biotechnol 19, 1348-1254, 2009.
37. Xiang WS, Zhang J, Wang JD, Jiang L, Jiang B, et al.: Isolation and identyfication of chlorinated genistein fromActinoplanes sp.HBDN08with antioxidant and antitumor activities. J Agric Food Chem 58, 1933-1938, 2010.
38. Klein R, Brown D, and Turnley AM: Phenoxodiol protects against cisplatin induced neurite toxicity In a PC-12 cell model.BMCNeuroscience 8, 61-67, 2007.
39. Aguero MF, Facchinetti MM, Sheleg Z, and Senderowicz AM: Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer 106 599-608, 2005.
40. Okobira T., Miyoshi K., Uezu K., Samurai K., Shinkai S., Molecular dynamic studies of side chain effect on the beta-1,3-D-glucan triple helix in aqueous solution. Biomacromolecules 9, 783-788, 2008.
41. Kony DB,DammW, Stoll S, vanGunsteren WF,Hünenberger PH. Explicitsolvent molecular dynamics simulations of the polysaccharide Schizophyllan in water. Biophysical Journal 93, 442-455, 2007.
42. Kubala L, Ruzickova J, Nickova K, Sandula J, Ciz M, et al.: The effect of (1-3)-β-D-glucans, carboxymethyloglucan and Schisophillan on human leukocytes in vitro. Carbohydrate Research 338, 2835-2840, 2003.
43. Yuguchi Y, Kumagai T, Wu M, Hirotsu T, and Hosokawa J: Gelation of xyloglucan in water/alkohol systems. Cellulose 11, 203-208, 2004.
44. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al.: New colorimetric cytotoxicity assay for anticancer-drug screening.JNatl Cancer Inst 82, 1107-1112, 1990.
45. Wietrzyk J, Chodýnski M, Fitak H, Wojdat E, Kutner A, et al.: Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 18, 447-457, 2007.
46. ReersM, Smith TW, and Chen LB: J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30, 4480-4486, 1991.
47. Kim R, Emi M, Tanabe K, Uchida Y, and Arihiro K: The role of apoptotic or nonapoptotic cell heath in determining cellular response to anticancer treatment. EJSO 32, 269-277, 2006.
48. Dixon RA and Ferreira D: Genistein. Phytochem 60, 205-211, 2002.
49. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJJ, and Badger TM: Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Amer J Clin Nutr 76, 588-594, 2002.
50. Simons AL, Renouf M, Murphy PA, and Hendrich S: Greater apparent absorption of flavonoids is associated with lesser human fecal flavonoid disappearance rates. J Agric Food Chem 58, 141-147, 2010.
51. Booth C, Hargreaves DF, Hadfield JA, McGown AT, and Potten CS: Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. Br J Cancer 80, 1550-1557, 1999.
52. Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DF, et al.: In vitro toxivity, pharmacokinetics, and anticancer activity of genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 4, 1125-1134, 1998.
53. Ek O, Yanishevski Y, Zeren T, Waurzyniak B, Gunther R, et al.: In vivo toxicity and pharmacokinetic features of B43(anti-CD19)-genistein immunoconjugate. Leuk Lymphoma 30, 389-394, 1998.
54. Messinger Y, Yanishevski Y, Ek O, Zeren T, Waurzyniak B, et al.: In vitro toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin Cancer Res 4, 165-170, 1998.
55. Mazurek AP,Kozerski L, Sadlej J, Kaw- ecki R, Bednarek E, et al.:Genistein complexes with amines: Structure and properties. J Chem Soc Perkin Trans 2, 1223-1230, 1998.
56. Meng QH, Wahala K, Adlercreutz H, and Tikkanen MJ: Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by lowdensity lipoprotein particles into cultured U937 cells. Life Sci 65, 1695-1705, 1999.
57. Polkowski K, Popiołkiewicz J, Krzeczynski P, PuckoW, Zegrocka-Stendel O, et al.: Cytostatic and cytotoxic activity of synthetic genistein glycosides against human cancer cell lines. Cancer Lett 203, 59-69, 2004.
58. RusinA,Krawczyk Z,Grynkiewicz G, Gogler A, Zawisza-Puchałka J, et al.: Synthetic derivatives of genistein, their properties and possible application. Acta Biochim Pol 57, 23-34, 2010.
59. RusinA, Zawisza-Puchałka J,KujawaK,Gogler-Pigłowska A,WietrzykA, et al.: Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells. Bioorg Med Chem 19, 295-305, 2011.
60. McCall JL, Burich RA, and Mack PC: GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk Res 34(1), 69-76, 2010.